Literature DB >> 32532560

[Update on beta blockers in 2020].

T Bejan-Angoulvant1, D Angoulvant2.   

Abstract

Beta-blockers (BB) are an heterogenous set of molecules actively blocking β adrenergic receptors. Their pharmacological properties depend on their various effects on the adrenergic signalling. Although they are no longer a first-choice treatment in hypertensive patients, they remain a cornerstone of pharmacological strategy in several cardiovascular diseases such as stable angina, heart failure, arrythmia and aortic related connective diseases. Beyond their usual non cardiovascular indications such as migraine, hepatic cirrhosis, glaucoma, infantile hemangioma, and hyperthyroidism, new therapeutic fields are under scrutiny. Potential BB therapeutic repurposing is being investigated in COPD and cancer patients. This narrative review first encompasses the basic pharmacological knowledge that may be useful for the clinician. Then it will detail BB main indications before exploring new therapeutic fields.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Adverse events; Beta-blockers; Bêtabloquants; Drug repositioning; Effets indésirables; Indications; Pharmacologie; Pharmacology; Repositionnement thérapeutique

Year:  2020        PMID: 32532560     DOI: 10.1016/j.revmed.2020.04.007

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  1 in total

Review 1.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.